People |

 Executive Board

Professor Duncan Jodrell, DM MSc FRCPE – Director, Researcher and Medical Oncologist


Duncan is Professor of Cancer Therapeutics at the University of Cambridge. Also, he is a Senior Group Leader and Head of the Pharmacology and Drug Development Group at the Cancer Research UK Cambridge Institute.  He is also the Cambridge Experimental Cancer Medicine Centre (ECMC) Lead for Early Phase Trials and an honorary consultant at Addenbrookes Hospital. 

Duncan is a fully trained and accredited Medical Oncologist who completed his doctoral thesis work at the Institute of Cancer Research, generating data pivotal to the selection of raltitrexed for the treatment of patients with cancer.  He undertook post-doctoral research at the University of Maryland, before returning to the Royal Marsden Hospital and subsequently the Beatson Oncology Centre, where he completed his clinical speciality training. 

In 1994, Duncan joined the medical faculty at the University of Edinburgh where, in addition to his clinical practice, he established a research team undertaking Early Phase clinical trials and a pharmacology laboratory.  He was awarded a personal chair by the University of Edinburgh in 2006 and in 2008 he was elected to the Chair of Cancer Therapeutics in Cambridge. 

Since moving to Cambridge, he has been instrumental in establishing the specialist oncology clinic for patients with pancreatic cancer (in 2009), which, together with his research activity in cancer therapeutics were major factors in Cambridge's successful application to become the Regional Centre for Pancreatic Cancer (in 2010).  As the Cambridge ECMC Lead for Early Phase Trials, he manages a research team and clinic, allowing patients across the Anglia region to access new therapies for cancer.

As a Senior Group Leader in the Cancer Research UK Cambridge Institute, Duncan undertakes research into new therapies for patients with cancer.  He also collaborates closely with imaging specialists in both the Institute and Addenbrookes Hospital, incorporating novel molecular imaging approaches into Early Phase trials of cancer therapeutics.